Agilent February 11, 2026 Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC) - Business Wire This article's full content could not be retrieved due to source site restrictions. Read full story on Agilent